Cervomed Inc (CRVO) Stock Price, Quote & News

Company Profile

CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurologic...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 744 4400

Website: www.cervomed.com

Address:

20 Park Plaza, Suite 424, Boston, United States

BPler Mar. 7 at 8:32 AM

$CRVO "Building on these preclinical results, CervoMed will be advancing neflamapimod into the clinic through the EXPERTS-ALS Platform." https://www.drugdiscoverynews.com/how-close-are-scientists-to-stopping-als-in-its-tracks-17057

2 · Reply

BPler Mar. 6 at 2:55 PM

$CRVO Last time it was at this level in Oct/Nov 2025

0 · Reply

BPler Mar. 6 at 2:32 PM

$CRVO Today, first time in months(!) the borrow fee fall under 7%, and is now at 6.87% https://fintel.io/de/ss/us/crvo

0 · Reply

BPler Mar. 6 at 8:46 AM

$CRVO . According to MarketBeat, CervoMed has a consensus rating of “Moderate Buy” and an average target price of $22.17. https://www.defenseworld.net/2026/03/06/d-boral-capital-reaffirms-buy-rating-for-cervomed-nasdaqcrvo.html

0 · Reply

BPler Mar. 5 at 7:41 PM

$CRVO Today, Chardan Capital, led by analyst Daniil Gataulin, has maintained its Buy rating for CervoMed (CRVO, Financial), keeping the price target steady at $15.00 USD. https://www.gurufocus.com/news/8681453/chardan-capital-maintains-buy-rating-for-crvo-crvo-stock-news

0 · Reply

BPler Mar. 5 at 7:40 PM

$CRVO JonesTrading analyst Soumit Roy maintained a Buy rating on CervoMed today and set a price target of $20.00. (...) The word on The Street in general, suggests a Strong Buy analyst consensus rating for CervoMed with a $22.75 average price target, implying a 437.8% upside from current levels. In a report issued on February 19, Roth MKM also maintained a Buy rating on the stock with a $19.00 price target. https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/586983/analysts-offer-insights-on-healthcare-companies-oculis-holding-ocs-and-cervomed-crvo/

0 · Reply

LowCountryHooker Mar. 5 at 6:33 PM

$CRVO CervoMed will be participating in two upcoming investor conferences in March. Management will host 1x1 investor meetings at the Leerink Global Healthcare Conference in Miami on March 11 and participate in a fireside chat at the 38th Annual ROTH Conference in Dana Point, CA on March 23 at 12:00–12:30 PM PT. A live webcast of the ROTH fireside chat will be available in the Events and Presentations section of our website: http://bit.ly/3OPpTEO

0 · Reply

BPler Mar. 5 at 12:35 PM

$CRVO https://ir.cervomed.com/news-releases/news-release-details/cervomed-participate-upcoming-investor-conferences-3

0 · Reply

BPler Mar. 5 at 7:53 AM

$CRVO FYI First time in months that the borrow fee to short fell under 7.5%. Indicates a minor partly slow covering before earnings call. But historically this ticker barely reacted in Alignment with good news. If the theory of one user, forget the name sorry, is right, good news usually will be seen 2-3 days after it came out. Let's see 🙆‍♂️ https://fintel.io/ss/us/crvo

0 · Reply

BPler Mar. 4 at 9:01 PM

$CRVO On March 4, 2026, analyst Jason Kolbert from D. Boral Capital reaffirmed his Buy rating for CervoMed (CRVO), maintaining the price target at $31.00 USD. https://www.gurufocus.com/news/8678488/cervomed-crvo-analyst-rating-update-buy-rating-maintained-by-d-boral-capital-crvo-stock-news

0 · Reply

CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies

Feb 17, 2026, 8:00 AM EST - 18 days ago

CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

SCYX

Dec 4, 2025, 5:00 PM EST - 3 months ago

CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies

Dec 2, 2025, 7:00 AM EST - 3 months ago

CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)

Nov 24, 2025, 7:00 AM EST - 3 months ago

CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Oct 20, 2025, 8:00 AM EDT - 4 months ago

CervoMed to Present at the Emerging Growth Conference

Oct 8, 2025, 11:54 AM EDT - 5 months ago

CervoMed Drug Cut Dementia Progression Risk By 75% In Trial

Oct 8, 2025, 7:00 AM EDT - 5 months ago

CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies

Oct 2, 2025, 8:00 AM EDT - 5 months ago

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

Sep 17, 2025, 7:30 AM EDT - 6 months ago

CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference

Sep 3, 2025, 8:00 AM EDT - 6 months ago

CervoMed to Participate in Upcoming Investor Conferences

Jul 28, 2025, 11:20 AM EDT - 7 months ago

CervoMed's Dementia Data Show Slowed Disease Progression

Jul 28, 2025, 7:00 AM EDT - 7 months ago

CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration

Jul 8, 2025, 7:00 AM EDT - 8 months ago

CervoMed Announces Late-Breaking Presentations at Alzheimer's Association® International Congress 2025

May 12, 2025, 8:00 AM EDT - 10 months ago

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Mar 31, 2025, 2:34 PM EDT - 1 year ago

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

CMRX CVS GERN LLY NVO SEPN

Mar 25, 2025, 8:00 AM EDT - 1 year ago

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)

Mar 22, 2025, 2:55 AM EDT - 1 year ago

CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats

Mar 10, 2025, 4:05 PM EDT - 1 year ago

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

Jan 29, 2025, 8:00 AM EST - 1 year ago

CervoMed to Present at the 8th International Lewy Body Dementia Conference

Dec 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 10, 2024, 11:37 AM EST - 1 year ago

CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets

Dec 10, 2024, 10:10 AM EST - 1 year ago

CervoMed's stock craters 77% after failed trial of treatment for rare brain disease

Dec 10, 2024, 7:33 AM EST - 1 year ago

CervoMed's dementia drug fails to meet mid-stage trial goals

Dec 10, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

Nov 27, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

Nov 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Nov 8, 2024, 9:55 AM EST - 1 year ago

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

Nov 4, 2024, 8:00 AM EST - 1 year ago

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

Oct 29, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

Oct 2, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

Aug 22, 2024, 8:00 AM EDT - 1 year ago

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

Jul 30, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

Jul 17, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in the Emerging Growth Conference

Jul 11, 2024, 8:51 AM EDT - 1 year ago

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

Jun 11, 2024, 8:00 AM EDT - 1 year ago

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

May 20, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Appoint William Elder as Chief Financial Officer

May 15, 2024, 8:00 AM EDT - 1 year ago

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Apr 2, 2024, 2:59 AM EDT - 2 years ago

CervoMed: H2 2024 Data For DLB Program A Major Inflection Point

Apr 1, 2024, 8:00 AM EDT - 2 years ago

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Mar 28, 2024, 8:30 AM EDT - 2 years ago

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

Mar 5, 2024, 8:00 AM EST - 2 years ago

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

Feb 21, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the BIO CEO and Investor Conference

Feb 12, 2024, 8:00 AM EST - 2 years ago

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

Feb 7, 2024, 8:30 AM EST - 2 years ago

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

Feb 5, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the Emerging Growth Conference 67

Jan 5, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the Emerging Growth Conference 66

Nov 13, 2023, 7:00 AM EST - 2 years ago

CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights

Oct 25, 2023, 2:50 PM EDT - 2 years ago

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies

Oct 24, 2023, 7:00 AM EDT - 2 years ago

CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias

BPler Mar. 7 at 8:32 AM

2 · Reply

BPler Mar. 6 at 2:55 PM

$CRVO Last time it was at this level in Oct/Nov 2025

0 · Reply

BPler Mar. 6 at 2:32 PM

$CRVO Today, first time in months(!) the borrow fee fall under 7%, and is now at 6.87% https://fintel.io/de/ss/us/crvo

0 · Reply

BPler Mar. 6 at 8:46 AM

0 · Reply

BPler Mar. 5 at 7:41 PM

0 · Reply

BPler Mar. 5 at 7:40 PM

0 · Reply

LowCountryHooker Mar. 5 at 6:33 PM

0 · Reply

BPler Mar. 5 at 12:35 PM

$CRVO https://ir.cervomed.com/news-releases/news-release-details/cervomed-participate-upcoming-investor-conferences-3

0 · Reply

BPler Mar. 5 at 7:53 AM

0 · Reply

BPler Mar. 4 at 9:01 PM

0 · Reply

Messerschmittbf109 Mar. 4 at 6:27 PM

$CRVO 35 M of cap.. we are a mosquito shit in a commercial planet full of big sharks

0 · Reply

Messerschmittbf109 Mar. 4 at 6:24 PM

$CRVO BOSTON - CervoMed Inc. (NASDAQ:CRVO) announced today that it has completed a Phase 1 study evaluating a stable crystalline form of neflapimod and selected a dosage regimen of 50mg three times a day for its planned Phase 3 trial in dementia with Lewy bodies. The announcement comes as the biotech company, with a market capitalization of $37.1 million, is trading at $4.01 per share, down almost 61% in the last six months despite having recorded a gain of 89% in the last year.

0 · Reply

BPler Mar. 4 at 6:24 PM

$CRVO -50% in 3 months, despite all positive news, is not dilution fear, looks more like a weird combination of swing traders, instutional buy-in with lending shares (over 7% fees) and bleeding out on constant short pressure. And dilution is not the wanted solution for management, if they bet on that, they would have done this months ago for a higher price. Like $ALMS or other biotech you usually try to dilute on good news as your fair company value would go up. Only incompetent management does dilute on bad news as a result on bad management. I understand any negative sentiment here from an emotional point, but I just don't see the overwhelming evidence for a bear case which says this company is worth so less as the market cap is today. Even fucking $MS made them a benefical owner, they have like 1000% better analysis insights as my 2cents.

1 · Reply

Messerschmittbf109 Mar. 4 at 6:21 PM

$CRVO amazing red yet …lost all daily gain The company plans to start a global Phase 3 trial in dementia patients with Lewy bodies in the second half of 2026, subject to the availability of funding. According to the analysis of InvestingPro, CervoMed holds more liquidity than debt in its balance sheet and maintains liquid assets that exceed short-term bonds, positioning the company to finance ongoing operations. The stock appears undervalued based on InvestingPro's Fair Value analysis, with analysts setting price targets between $15 and $31.

0 · Reply

Messerschmittbf109 Mar. 4 at 6:19 PM

$CRVO The pharmacokinetic profile of the new stable crystalline form largely overlaps with the pharmaceutical product used in the extension of the Phase 2b trial, according to a press release. The company increased the dose from 40mg to 50mg to ensure that the plasma concentrations of the drug correspond to those observed with the batch of pharmaceutical product that demonstrated clinical and biomarker activity in the extension phase of the RewinD-LB trial. "The process historically used to produce neflamapimod produced pharmacological substances containing multiple solid-state forms, also called polymorphs," said Marco Verwijs, Executive Vice President of Technical Operations at CervoMed. "With prolonged storage, less stable and higher solubility polymorphs converted to a more stable form but with lower solubility, resulting in a decrease in bioavailability when administered to patients."

0 · Reply

BPler Mar. 4 at 5:09 PM

$CRVO Gives me some üextra confidence that they didnt wait for earnings with this news. Undervalued company, still adding on dips. 16th March will telll

1 · Reply

BPler Mar. 4 at 2:44 PM

$CRVO Immediately gets shorted on positive news. Unreal, takes just one whale to blow this micro cap up from getting hammered down all the time.

1 · Reply

Stu_padasso Mar. 4 at 2:41 PM

$CRVO Hear comes the red seemingly good news and it goes red…always i really believe that dilutive funding is in the works share count to at least double more likely triple

1 · Reply

LowCountryHooker Mar. 4 at 2:40 PM

$CRVO Today, we announced our successful completion of a Phase 1 healthy volunteer study evaluating the pharmacokinetics (PK) of drug product containing a new, stable crystal form of neflamapimod. Following our evaluation of the data, we’ve selected 50 mg of the stable crystal form of neflamapimod as the dose for our planned Phase 3 study in patients with dementia with Lewy bodies (DLB). We believe the 50mg dose will achieve the plasma drug concentrations observed in our Phase 3 trial with the drug product batch that demonstrated significant clinical and biomarker activity in the extension phase of the Phase 2b RewinD-LB trial. You can read more here: https://lnkd.in/ekrT2wS6 #neflamapimod #Phase3 #DLB

0 · Reply

LowCountryHooker Mar. 4 at 2:39 PM

$CRVO I increased my position by 15% yesterday at 3.71. Wish I would have doubled down.

0 · Reply

BPler Mar. 4 at 1:17 PM

$CRVO https://ir.cervomed.com/news-releases/news-release-details/cervomed-announces-selection-formulation-and-dosing-regimen

1 · Reply

DARKP00L Mar. 4 at 1:08 PM

$CRVO 07:32 on Mar. 04 2026 CervoMed Completes Phase 1 Volunteer Trial To Evaluate Pharmacokinetics Of Drug Product Having Only New Stable Crystal Form Of Neflamapimod, Related Updates Regarding Its Planned Phase 3 Trial In Dementia With Lewy Bodies #tradeideas

0 · Reply

Market Cap	38.03M
Revenue (ttm)	9.74M
Net Income (ttm)	-16.29M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-167.25%
Debt to Equity Ratio	0.00

Volume	45,500
Avg Vol	83,458
Day's Range	N/A - N/A
Shares Out	9.25M
Stochastic %K	34%
Beta	-0.77
Analysts	Strong Sell
Price Target	$22.43